



Miraca Holdings Inc.
Business Results for
The First Quarter of FY2017
(Three-month period ended June 30, 2017)


August 1, 2017

Please be aware of the following:

- * The financial information provided on this material has been prepared in accordance with Japanese GAAP in principle.
- * Figures and ratio in this material are rounded to the appropriate unit in principle, and the sums of the individual figures in each table do not always correspond to the total, because of rounding.
- * Abbreviations:
 - IVD: In Vitro Diagnostics (business) CLT: Clinical Laboratory Testing (business)
 - HR: Healthcare Related (business)
 - Op. income: Operating income Or. income: Ordinary income

※ Exchange rate : FY2016 1Q:1USD = 108.26JPY 1EURO = 122.18JPY FY2017 1Q:1USD = 111.11JPY 1EURO = 122.21JPY
--

Transition of Consolidated Sales




Consolidated Sales (vs. FY2016 1Q)


Net sales was same level as previous year

(including currency exchange impact)

(¥ billion)




Transition of Consolidated Op. Income



Consolidated Op. Income (vs. FY2016 1Q)


Op. income was same level as previous year
(including currency exchange and depreciation method change[※] impact)

(¥ billion)



※ Depreciation method was changed from fixed percentage to straight-line
: +0.26 bn yen (CLT: +0.19, IVD: +0.07)


Transition of Consolidated EBITDA



※ EBITDA = Operating income + Depreciation + Amortization of goodwill

Transition of Consolidated Ord. Income

Ord. income increased due to smaller foreign exchange losses



Major item of non-operating losses

【FY2016 1Q】


- Share of loss of entities accounted for using equity method
-¥0.3bn
- Foreign exchange losses
-¥0.7bn

【FY2017 1Q】

- Share of loss of entities accounted for using equity method
-¥0.2bn
- Foreign exchange losses
-¥0.05bn

Transition of Consolidated Net Profit

Provision for loss on litigation was recognized in 1Q/FY16



Major item of extraordinary losses

【FY2016 1Q】

- Provision for loss on litigation
-¥3.0bn

【FY2017 1Q】

- (Nothing in particular)

FY2017 1Q Results by Business Segment

Net sales was same level as previous year, while EBITDA decreased 8%

(¥ billion)

	1Q/FY2016	1Q/FY2017	Y/Y Variation	
Net Sales	52.1	52.2	+ 0.10	0.2%
CLT	34.2	33.7	- 0.43	-1.3%
IVD	10.8	11.4	+ 0.59	5.5%
HR	7.1	7.0	- 0.06	-0.9%
Op. Income	※1 7.3 14.0% ※3	※1 7.2 13.8%	- 0.10	-1.4%
CLT	3.4 10.0%	3.1 9.2%	- 0.30	-8.9%
IVD	3.0 27.7%	3.3 28.9%	+ 0.29	9.8%
HR	0.8 11.6%	0.9 13.3%	+ 0.12	14.0%
Ord. Income	6.3 12.0%	6.9 13.2%	+ 0.63	10.0%
Profit attributable to owners of parent	2.0 3.8%	4.6 8.8%	+ 2.61	131.7%
EBITDA ※2	10.7 20.6%	9.8 18.9%	- 0.88	-8.2%


※1 Op. income includes Miraca Corporate and segmentation adjustment (FY16 : +0.07、FY17 : -0.13)

※2 EBITDA = Operating income + Depreciation + Amortization of goodwill

※3 Figures shown in the upper right corner in blue are each profit margin

CLT Business

(¥ billion)



Net sales : - 0.4
Op. income : - 0.3

◆ Japan

Net sales : +0.07, Op. income : +0.17

- Sales increase by acquisition of new accounts in FMS/Branch lab business
- Sales decrease by HCV-related test decline
- Decrease in depreciation due to Navi-Lab project termination (0.37)

◆ Global

Net sales : -0.46, Op. income : -0.45


- Volume increase and price cut resulted in sales decrease
- Currency exchange impact on sales: +0.18

【MLS (before goodwill amortization, J-GAAP)】

Net sales : -\$5.9M, Op. income : -\$4.5M

IVD Business

(¥ billion)



Net sales : +0.6

Op. income : +0.3

Net sales

◆ Lumipulse

- Same level as previous year

◆ OEM & Raw Material Supply

- Stable growth

◆ Other

- Contribution by sales of coagulation product (Stago products)


※ Currency exchange impact: +0.09

Op. income

- ◆ Increase with sales growth

HR Business

(¥ billion)



Net sales : - 0.1

Op. income : +0.1

◆ Sterilizing

Net sales: +0.12, Op. income :-0.05

- Sales growth achieved through development of new accounts

◆ Clinical Trials

Net sales: -0.20, Op. income :+0.02

- Sales decrease due to delay of some parts of expected PJ's sales contribution

◆ Others

Net sales: -0.02, Op. income :+0.14

- OP increase by disposal of some parts of provision

* Pharmaceutical and Cosmetics Analysis business has been transferred to CLT segment. The past results are adjusted accordingly.

【Contact information】

Miraca Holdings Inc.

Investor and Public Relations Department

Email : mhd.ir@miraca.com

Disclaimer regarding forward-looking statement:

The performance forecast provided in this document is prepared by the management based on currently available information and various hypotheses and ideas including significant risks or uncertainties. Please be aware that the actual performance may turn out to be different from the forecast as a result of various contributing factors.

Factors affecting the performance include, among others, aggravation of the economic situation, fluctuation of the exchange rate, change of regulatory, statutory, and administrative requirements, delayed launch of new products, pressures from the product strategies of competitive companies, and decline of the sales potential of existing products.